Service de maladies infectieuses et tropicales, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, 5, rue Thomas-Mann, 75013 Paris, France.
Service de maladies infectieuses et tropicales, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, 5, rue Thomas-Mann, 75013 Paris, France.
Med Mal Infect. 2018 Aug;48(5):318-326. doi: 10.1016/j.medmal.2018.01.009. Epub 2018 Feb 9.
Preexposure prophylaxis of HIV with antiretroviral drugs is a prevention tool available in France since 2016, combined with the prevention methods already used (condoms, post-exposure treatment, rapid treatment of diagnosed HIV infections, etc.). It is targeted at populations at high risk of HIV infection, especially men who have sex with men, for whom traditional prevention methods are insufficient. We collected clinical research data, which resulted in the launch of preexposure prophylaxis in the United States and then elsewhere in the world, safety, tolerability and cost data, as well as ongoing research data (new molecules/methods of administration). We also provided an update of its use in France.
抗逆转录病毒药物的 HIV 暴露前预防是 2016 年在法国推出的一种预防工具，与已经使用的预防方法（避孕套、暴露后治疗、已诊断 HIV 感染的快速治疗等）相结合。它针对的是感染 HIV 风险较高的人群，特别是男男性行为者，因为传统的预防方法对他们效果有限。我们收集了临床研究数据，这些数据促成了暴露前预防在美国和其他地方的推出，还包括安全性、耐受性和成本数据，以及正在进行的研究数据（新分子/给药方法）。我们还更新了其在法国的使用情况。
